

JUL 20 2004

Please type a plus sign (+) inside this box → [ + ]

PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 5

## COMPLETE IF KNOWN

Application Number	10/404512
Confirmation Number	6502
Filing Date	April 1, 2003
First Named Inventor	Chen et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	9188&

## U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			


## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
SHS		EP 0,508,701B1	10-14-1992	Quest International B.V.		
		EP 0,862,863B1	09-09-1998	Societe Des Products Nestle S.A.		
		EP 1,312,667A1	05-21-03	Wakamoto Pharmaceutical Co., LTD		
		W0 00/41707A1	07-20-2000	Enterprise Ireland		
		W0 00/42168A2	07-20-2000	Enterprise Ireland		
		W0 02/083879A2	10-24-2002	Alimentary Health LTD.		
		W0 03/010297A1	02-06-2003	Alimentary Health LTD.		
		W0 03/010298A1	02-06-2003	Alimentary Health LTD.		
		W0 03/010299A1	02-06-2003	Alimentary Health LTD.		
EXAMINER			DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Please type plus sign (+) inside this box -> (+)

PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 5

### COMPLETE IF KNOWN

Application Number	10/404512
Confirmation Number	6502
Filing Date	April 1, 2003
First Named Inventor	Chen et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	9188&


### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<del>AGA, Abstracts, Gastroenterology Vol. 110 No. 4</del>	
		<del>HENRY J. BINDER, M.D., "Genes, Bacteria and T Cells: Ingredients for Inflammatory Bowel Disease", Selected Summaries, Gastroenterology 1998; 115: 1605-1609, Vol. 115, No. 6</del>	
		<del>O'MAHONY ET AL., "Probiotic Bacteria and the Human Immune System", Dept. Microbiology and Medicine, National Food Biotechnology Centre, University College Cork &amp; Dept. Surgery, Mercy Hospital, Cork Ireland</del>	
		<del>O'HALLORAN ET AL., "Adhesion of Potential Probiotic Bacteria to Human Epithelial Cell Lines", Departments of Microbiology and Medicine, University College, Mercy Hospital, Cork, Ireland, Dept. of Surgery, Mercy Hospital, Cork, Ireland</del>	
SHS		STALLMACH ET AL., "Induction and Modulation of Gastrointestinal Inflammation", Trends Immunology Today, October 1998, Vol. 19 No. 10 pages 438-441	
↓		MARTEAU ET AL., "Potential of Using Lactic Acid Bacteria for Therapy and Immunomodulation in Man", FEMS Microbiology Reviews 12 (1993) 207-220	
↓		FERGUS SHANAHAN, "The Intestinal Immune System", Physiology of the Gastrointestinal Tract, Third Edition, 1994	
		<del>VITTORIO SCARDOVI, "Irregular Nonsporing Gram-Positive Rods", Genus Bifidobacterium Orla-Jensen 1924, 472</del>	
SHS		SCHMITT ET AL., "The Immunostimulatory Function of IL-12 in T-Helper Cell Development and Its Regulation by TGF- $\beta$ , IFN- $\gamma$ and IL-4", Chem Immunet Basel Karger, 1997, Vol. 68, pp 70-85	
↓		PANWALA ET AL., "A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdr1a, Spontaneously Develop Colitis", The American Association of Immunologists, 1998, The Journal of Immunology, 1998 161: 5733-5744	
↓		O'MAHONY ET AL., "Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL-10 Knockout Mice", Aliment Pharmacol Ther 2001; 15: 1219-1225	
↓		MEDAGLINI ET AL., "Mucosal and Systemic Immune Responses to a Recombinant Protein Expressed on the Surface of the Oral Commensal Bacterium Streptococcus gordonii after oral colonization", Proc. Natl. Acad. Sci. USA Vol. 92, pp 6868-6872, July 1995 Medical Sciences	
		<del>MCCRACKEN ET AL., "Probiotics and the Immune System"</del>	
		<del>MCBREARTY ET AL., "Probiotic Bifidobacteria and Their Identification Using Molecular Genetic Techniques", Teagasc, Dairy Products Research Centre, Moorepark, Fermoy, Co. Cork, Ireland</del>	
		<del>Department of Microbiology, University College Cork, Ireland</del>	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number  
Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 3 of 5

## COMPLETE IF KNOWN

Application Number	10/404512
Confirmation Number	6502
Filing Date	April 1, 2003
First Named Inventor	Chen et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	9188&

## NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<del>O'MAHONY ET AL., "Probiotic Bacteria and Pathogenic Bacteria Elicit Differential Cytokine Responses From Dendritic Cells", XP-001097379</del>	
SHS		CHARTERIS ET AL., "Antibiotic Susceptibility of Potentially Probiotic Bifidobacterium Isolates From the Human Gastrointestinal Tract", Letters in Applied Microbiology 1998, 26, 333-337	
		MC GEE ET AL., "A Synergistic Relationship Between TNF- $\alpha$ , IL-1 $\beta$ , and TGF- $\beta$ 1 on IL-6 Secretion by the IEC-6 Intestinal Epithelial Cell Line", Immunology 1995 86 6-11	
		BOUHNİK ET AL., "Effects of Bifidobacterium SP Fermented Milk Ingested With or Without Inulin on Colonic Bifidobacteria and Enzymatic activities in Healthy Humans" European Journal of Clinical Nutrition (1996) 50, 269-273	
		CHARTERIS ET AL., "Development and application of an In Vitro Methodology to Determine the Transit Tolerance of Potentially Probiotic Lactobacillus and Bifidobacterium Species in the Upper Human Gastrointestinal Tract" Journal of Applied Microbiology 1998, 84, 759-768 - XP 000929203	
		CHARTERIS ET AL., "Antibiotic Susceptibility of Potentially Probiotic Bifidobacterium Isolates from the Human Gastrointestinal Tract, "Letters of Applied Microbiology 1998, 26, 333-337	
		CHARTERIS ET AL., "Selective Detection, Enumeration and Identification of Potentially Probiotic Lactobacillus and Bifidobacterium Species in Mixed Bacterial Populations", International Journal of Food Microbiology 35 (1997) 1-27	
		CHEVALIER ET AL., "Detection of Bifidobacterium Species by Enzymatic Methods", Journal of Applied Bacteriology 1990, 68, 619-624	
		COLLINS ET AL., "Selection of Probiotic Strains for Human Applications", In. Dairy Journal 8 (1998) 487-490	
		<del>DONNE ET AL., "Probiotics: From Myth to Reality. Demonstration of Functionality in Animal Models of Disease and in Human Clinical Trials" XP-000929176</del>	
SHS		GIBSON ET AL., "Dietary Modulation of the Human Gut Microflora Using Prebiotics", Journal of Nutrition (1998) 80, Suppl. 2 S209-S212	
		CHARTERIS ET AL., "Effect of Conjugated Bile Salts on Antibiotic Susceptibility of Bile Salt-Tolerant Lactobacillus and Bifidobacterium Isolates", Journal of Food Protection Vol. 63, No. 10, 2000, pages 1369-1376	
		<del>ARAI ET AL., "Cytokines: Coordinators of Immune and Inflammatory Responses", Annu. Rev. Biochem. 90, 59-792-826</del>	
SHS		GROUX ET AL., "Regulatory T Cells and Inflammatory Bowel Disease", Viewpoint Immunology Today October 1999	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

SHEET 5 of 5

**COMPLETE IF KNOWN**

Application Number	10/404512
Confirmation Number	6502
Filing Date	April 1, 2003
First Named Inventor	Chen et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	9188&

**NON PATENT LITERATURE DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	†
		GBOLUX ET AL., "Regulatory T Cells and Inflammatory Bowel Disease", <u>Viewpoint Immunology Today</u> , October 1999	
SHS		GASCHE ET AL., "IL-10 Secretion and Sensitivity in Normal Human Intestine and Inflammatory Bowel Disease", <u>Journal of Clinical Immunology</u> Vol. 20, No. 5, 2000	
		HOMMES ET AL., "Anti- and Proinflammatory Cytokines in the Pathogenesis of Tissue Damage in Crohn's Disease", 2000 Lippincott Williams and Wilkins 1363-1950	
		MCKAY ET AL., "Review article: In Vitro Models in Inflammatory Bowel Disease", <u>Aliment Pharmacol Ther</u> , 1997; 11 (Suppl. 3): 70-80	
		L. LAKATOS, "Immunology of Inflammatory Bowel Diseases", <u>Acta Physiologica Hungarica</u> , Vol. 87 (4), pp. 355-372 (2000)	
		POWRIE ET AL., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in Scid Mice Reconstituted with CD45Rbhi CD4+ T Cells", <u>Immunity</u> Vol. 1, 553-562, October, 1994	
		VAN DAMME ET AL., "The Proportion of Th1 Cells, Which Preval in Gut Mucosa, is Decreased in Inflammatory Bowel Syndrome", <u>Clin Exp Immunol</u> 2001; 125:383-390	
EXAMINER	Shulamith H. Shafer		DATE CONSIDERED 08/07/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [ + ]

SUPPL. PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Substitute for form 1449A/PTO

COMPLETE IF KNOWN

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2



Application Number	10/810,358
Confirmation Number	1244
Filing Date	March 26, 2004
First Named Inventor	Chen et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	9188R&

## U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup>	(if known)			
SHS	1	US-5,853,697		12/29/1998	The United State Of America	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
SHS	2	WO 94/04180A2			03/03/1994	Schering Corp.		
SHS	3	WO 94/04180A3			03/03/1994	Schering Corp.		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [+]

PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p> <p>SHEET 2 of 2</p>	<b>COMPLETE IF KNOWN</b>	
	Application Number	10/810,358
	Confirmation Number	1244
	Filing Date	March 26, 2004
	First Named Inventor	Chen et al.
	Group Art Unit	1616
	Examiner Name	
Attorney Docket Number	9188R&	

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SHS	4	HILDESHEIM ET AL., "Simultaneous Measurement Of Several Cytokines Using Small Volumes Of Biospecimens", <u>Cancer Epidemiology, Biomarkers &amp; Prevention</u> , Vol. 11, pgs. 1477-1484, November 2002, XP002296946 abstract	
↓	5	ANDUS ET AL., "Imbalance Of The Interleukin 1 System In Colonic Mucosa – Association With Intestinal Inflammation And Interleukin 1 Receptor Agonist Genotype 2", <u>Gut</u> , Vol. 41, 1997, pages 651-657, page 654, column 2-page 655, column 1 figure 2D, XP002296947	
	6	ROGLER ET AL., "Cytokines In Inflammatory Bowel Disease", <u>World Journal of Surgery</u> , Vol. 22, 1998, pages 382-389, XP002296948 the whole document	
	7	O'CALLAGHAN ET AL., "Human Cytokine Production By Mesenteric Lymph Node Cells In Response To Probiotic And Pathogenic Bacteria", <u>Gastroenterology</u> , Vol. 122, No. 4 Suppl. 1, page A-151 DDW Meeting Abstract Nr. S1040, April 2002, XP009036734 the whole document	
	8	MCCARTHY ET AL., "Double Blind, Placebo Controlled Trial Of Two Probiotic Strains In Interleukin 10 Knockout Mice And Mechanistic Link With Cytokine Balance", <u>Gastroenterology</u> , Vol. 122, Nr. 4 Suppl. 1, pages A-389-A390 DDW Meeting Abstract Nr. T962, XP009036733 the whole document	
<b>EXAMINER</b> Shulamith H. Shafer		<b>DATE CONSIDERED</b> 08/04/2006	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

9188R& PTO-SB08  
(Revised for P&G use 10/8/2003)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/810358
		Confirmation Number	1244
		Filing Date	March 26, 2004
		First Named Inventor	Chen et al.
		Group Art Unit	1616
		Examiner Name	
		Attorney Docket Number	9188R&

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.